Quinoline derivatives as AXL kinase inhibitors

US9206130B2 · kind B2 · utility

Assignee

• Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. · US

Inventors

• Axel Ullrich · Portola Valley, US
• Pjotr Knyazev · Gauting, DE
• Yixiang Zhang · Beijing, CN
• Kéri György · Budapest, HU
• Laszlo Orfi · Budapest, HU
• Istvan Szabadkai · Budapest, HU

Key dates

• Filing date: Apr 16, 2009
• Grant date: Dec 8, 2015
• Expiry date: Feb 4, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Novel compounds which are inhibitors of receptor tyrosine kinases of the AXL receptor family are described herein. These compounds are suitable for the treatment or prevention of disorders associated with, accompanied by or caused by hyperfunction of a receptor of the AXL family. The compounds are suitable for the treatment of hyperproliferative disorders, such as cancer, particularly cancer metastases.